Extracorporeal Shock Wave Therapy Equipment For Achilles Tendonitis

Product Description

Extracorporeal Shock Wave Therapy (ESWT) Equipment For Musculoskeletal Disorders

SmartWave BS-SWT5000 for Physical Therapy.pdf

Extracorporeal Shock Wave Therapy works for many treatable medical conditions as a non-invasive solution for treating and healing pain, and is steadily increasing in use in the United States. And for a variety of good reasons.

Chronic pain as a result of injury or illness is one of the most difficult conditions for so many people to live with on a daily basis. It affects every aspect of a person’s day-to-day life and is also incredibly taxing on mental health and wellbeing.

What is Extracorporeal Shock Wave Therapy?
Extracorporeal Shock Wave Therapy (ESWT), sometimes referred to as EPAT Therapy or simply “Shockwave,” is a non-invasive therapy used to treat pain and promote healing by delivering high-energy sound waves to injured or damaged tissue during short treatment sessions.

Through the use of targeted ESWT therapy, inflamed tissue that causes pain will begin to regenerate because of increased blood circulation created by the treatments. Many patients see an improvement in their pain levels after as few as one or two sessions of ESWT.

Treatment with ESWT is beneficial for patients because there is no down time after the procedure, so time missing work, school or sports practice is not an issue for patients.

“Extracorporeal” means outside the body, and unlike surgery, Extracorporeal Shock Wave Therapy is completely noninvasive.

This form of nonsurgical procedure is ideal for patients who have tried more conservative options, such as resting, icing the effected areas, or decreasing activity levels, but have not seen any improvement in their pain levels or progress made with respect to their injuries healing.

Extracorporeal shockwave therapy (ESWT) began with an incidental observation of osteoblastic response pattern during animal studies in the mid-1980 that generated an interest in the application of ESWT to musculoskeletal disorders. In the past 10 to 15 years, shockwave therapy had emerged as the leading choice in the treatment of many orthopedic disorders including proximal plantar fasciitis of the heel, lateral epicondylitis of the elbow, calcific tendinitis of the shoulder and. non-union of long bone fracture. More recently, the use of ESWT had expanded to the treatment of patellar tendinopathy (jumper's knee) and Achilles tendinopathy, and avascular necrosis of the femoral head ESWT has gained significant acceptance from Europe (Germany, Austria, Italy and others) to South America (Brazil, Columbia, Argentina and others), Asia (Korea, Malaysia, Taiwan and others) and North America (Canada and USA), and this had led to the change of European Society for Musculoskeletal Shockwave Therapy to International Society for Musculoskeletal Shockwave Therapy (ISMST) in 2000. In USA, FDA (Food and Drug Administration) first approved the specific shockwave device, OssaTron (High Medical Technology, Lengwil, Switzerland, now Sanuwave/Alpharetta, GA) for the treatment of proximal plantar fasciitis in 2000 and lateral epicondylitis of the elbow in 2003. FDA also approved Epos (Dornier Medical System, Kennesaw, GA) for the treatment of plantar fasciitis and Sonocur (Siemens Medical Systems, Iselin, NJ) for the treatment of lateral epicondylitis of the elbow in 2002, Orthospec (Medispec, Germantown, MD) and Orbasone (Orthometrix, White Plains, NY) for the treatment of plantar fasciitis in 2005.

What can Extracorporeal Shock Wave Therapy (ESWT) Equipment For Musculoskeletal Disorders?

Sources of shock wave generation include electro-hydraulic, electromagnetic and piezoelectric principles. Electro-hydraulic shock waves are high-energy sound waves generated by high-pressure electrode water explosion.

Shock waves in urology (healing) are mainly used to disintegrate urolithiasis, while shock waves in orthotripsy are not used to break down tissue, but to induce tissue repair and regeneration.

Extracorporeal shock wave therapy (ESWT) has been used in musculoskeletal diseases for more than a decade, mainly for the treatment of exercise-related overuse tendinopathy, such as proximal heel fasciitis, lateral elbow gingivitis, calcification Or calcified tendinitis such as non-periarthritis and rickets.

The success rate is between 65% and 91%, with low complications and negligible.

ESWT is also used to treat long bone fractures, avascular necrosis of the femoral head, chronic and non-diabetic ulcers, and non-healing of ischemic heart disease. The vast majority of published papers show positive and beneficial effects.

The FDA (USA) first approved ESWT for the treatment of proximal plantar fasciitis and external epicondylitis in 2002. ESWT is a new non-invasive treatment with no risk of surgery or surgery, clinical ESWT Applications have steadily increased over the years.